Shanghai Junshi Biosciences Co.Ltd(688180) 3 announced on March 7 that recently, the company received the notice of approval for clinical trial of drugs approved and issued by the State Drug Administration, and the application for clinical trial of js001sc injection for the treatment of advanced nasopharyngeal carcinoma was approved. Js001sc injection is a subcutaneous injection preparation developed by the company on the basis of the listed product treprizumab injection (trade name: tuoyi?, product code: js001).
© China Stock Market News